000739 Apeloa Pharmaceutical
- 17.24
- +1.46+9.25%
Apeloa Pharmaceutical News
Apeloa Pharmaceutical Teams Up With Startup to Produce Biosynthetic Products; Shares Up 7%
apeloa pharmaceutical (000739.SZ): Buyback completed, repurchased 0.93% of shares.
On September 27, Gelonhui announced that as of September 26, 2024, Apeloa Pharmaceutical (000739.SZ) disclosed that the company has repurchased a total of 10,880,000 shares of the company through a share buyback special securities account in a centralized bidding trading manner, accounting for 0.93% of the current total share capital of the company, with a highest fill price of 15 yuan/share, a lowest fill price of 12.64 yuan/share, and a total transaction amount of RMB 153,070,084 (excluding transaction costs), the funds for repurchasing shares are from the company's own funds. This buyback complies with relevant laws and regulations, and is in line with the company's share buyback program, this buyback.
Apeloa Pharmaceutical (000739.SZ) has signed a strategic cooperation agreement with Baikui Rui.
Gelonghui 26th September | Apeloa Pharmaceutical (000739.SZ) announced that the company has cooperated with Baikuirui (Shenzhen) Biological Technology Co., Ltd. (hereinafter referred to as "Baikuirui") in an open and cooperative manner based on the principles of honesty, equality, and win-win situation. By complementing each other's advantages in existing products, production capacity, and technology, the two parties have achieved strong cooperation. In order to strengthen cooperation and establish a future-oriented global strategy partnership, both parties are willing to become strategic partners and have recently signed a "Strategic Cooperation Agreement". Baikuirui has developed and produced through its protein precision design and Smart Evolution machine learning algorithm platform.
Apeloa Pharmaceutical (000739.SZ): Apeloa Hong Kong plans to invest 2.75 million US dollars to subscribe for 815,900 shares of Series D preferred stock of Jixing Company.
Gelonghui September 19th | Apeloa Pharmaceutical (000739.SZ) announced that recently, Apeloa Hong Kong Limited, a subsidiary of Apeloa Pharmaceutical Co., Ltd., has jointly signed a "
Apeloa Pharmaceutical (000739.SZ): The design of the company's second larger capacity peptide production line is currently underway.
Apeloa Pharmaceutical (000739.SZ) stated on the investor interaction platform on September 18 that the company has built a polypeptide production line in August this year, which is equipped with two solid-phase synthesis reactors (200L and 500L respectively) and supporting facilities. The designed annual production capacity of the production line is approximately in the hundred kilograms range. Currently, the production line has undergone customer audits, and there are ongoing projects. The company is also designing a second polypeptide production line with a larger capacity.
Little Excitement Around Apeloa Pharmaceutical Co.,Ltd's (SZSE:000739) Earnings
gtja: The new signed orders for CXO in the first half of the year show a positive trend, and the API profitability is improving gradually by quarter.
In the first half of the year, CXO performance is under short-term pressure, with a positive trend in new signings; the API destocking is nearing completion, and profitability is improving quarter by quarter.
Apeloa Pharmaceutical (000739.SZ): has repurchased 0.93% of shares.
Apeloa Pharmaceutical (000739.SZ) announced that as of August 31, 2024, the company has repurchased a total of 10,880,000 shares of the company through a repurchase special securities account through centralized bidding trading, accounting for 0.93% of the current total share capital of the company. The highest fill price was 15 yuan per share, and the lowest fill price was 12.64 yuan per share. The total amount of fill price was RMB 0.153 billion (excluding transaction costs).
1.7% Earnings Growth Over 3 Years Has Not Materialized Into Gains for Apeloa PharmaceuticalLtd (SZSE:000739) Shareholders Over That Period
Apeloa Pharmaceutical (000739.SZ): It is expected that the demand for antibiotics will rebound slightly in the second half of the year.
On August 20th, Glory Medicaments reported at the investor relations event that the overall API sector of Apeloa Pharmaceutical (000739.SZ) is still under some pressure and there are no clear signs of rebound at the moment, especially for animal medicine and sartans. In terms of animal medicine, although pork prices are rising, animal medicine is still at a low level, such as flunixin. Sartans are also at their historical lows. Cephalosporin and penicillin are the company's two largest categories with a relatively stable competitive landscape, but demand has been weaker than in previous years since April, and it is expected that after pharmacy price comparisons, the end market inventory will be more cautious in the second half of the year.
Apeloa Pharmaceutical's H1 Profit Up 4%, Revenue Rises 8%; Shares Climb 3%
Apeloa Pharmaceutical: Summary of Half-Year Report in 2024.
Apeloa Pharmaceutical: Half-year report for the year 2024.
Apeloa Pharmaceutical (000739.SZ): net income of 625 million yuan in the first half of the year, a year-on-year increase of 3.96%.
Apeloa Pharmaceuticals (000739.SZ) announced its half-yearly report. During the reporting period, the company achieved a revenue of 6.429 billion yuan, a year-on-year increase of 7.96%, and a net profit attributable to shareholders of the listed company of 0.625 billion yuan, a year-on-year increase of 3.96%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 0.6 billion yuan, a year-on-year increase of 1.24%. In the first half of 2024, international geopolitical tensions are still complex, industry competition remains fierce, and the domestic economic recovery is still weak, and the investment and financing environment is still severe, which has brought great pressure and challenges to the company's operation and development.
Apeloa Pharmaceutical (000739.SZ) currently does not have any products related to vitamins.
Apeloa Pharmaceutical (000739.SZ) stated on the investor interaction platform on August 12th that, at present, the company does not have any vitamin-related products.
Apeloa Pharmaceutical Co.,Ltd's (SZSE:000739) Largest Shareholders Are Private Companies Who Were Rewarded as Market Cap Surged CN¥1.2b Last Week
Apeloa Pharmaceutical (000739.SZ) has spent a total of 0.153 billion yuan to repurchase 0.93% of its shares.
Apeloa Pharmaceutical (000739.SZ) announced on August 1st that by July 31, 2024, the company had repurchased 10,880,000 shares of company stock through a repurchase special securities account using centralized bidding trading method, accounting for 0.93% of the company's current total share capital, with a highest fill price of 15 yuan/share, a lowest fill price of 12.64 yuan/share, and a total transaction amount of RMB 0.153 billion (excluding transaction fees).
Apeloa Pharmaceutical Gets US FDA Approval for Hypertension, Chest Pain Tablets
Apeloa Pharmaceutical (000739.SZ): Metoprolol Succinate Sustained-Release Tablets Approved by the US FDA for Marketing.
Apeloa Pharmaceutical (000739.SZ) announced that its wholly-owned subsidiary, Zhejiang Jutai Pharmaceutical Co., Ltd., ...
Does Apeloa PharmaceuticalLtd (SZSE:000739) Have A Healthy Balance Sheet?
Analysis
Price Target
No Data
No Data